Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2014 (2014), Article ID 717598, 5 pages
http://dx.doi.org/10.1155/2014/717598
Clinical Study

Golimumab as Rescue Therapy for Refractory Immune-Mediated Uveitis: A Three-Center Experience

1Department of Ophthalmology, University Hospital of León, 24071 León, Spain
2Uveitis Unit, University Hospital of León, 24071 León, Spain
3Institute of Biomedicine (INBIOMED), University of León, León, Spain
4Department of Rheumatology, University Hospital “Marques de Valdecilla”, IFIMAV, 39008 Santander, Spain
5Department of Ophthalmology, University Hospital “Clínic”, 08036 Barcelona, Spain
6Department of Rheumatology, University Hospital of León, 24071 León, Spain
7Department of Immunology, University Hospital of León, 24071 León, Spain

Received 9 March 2014; Revised 25 April 2014; Accepted 12 May 2014; Published 28 May 2014

Academic Editor: Dennis Daniel Taub

Copyright © 2014 Miguel Cordero-Coma et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. B. Nussenblatt, “Philosophy, goals, and approaches to medical therapy,” in Uveitis: Fundamentals and Clinical Practice, R. B. Nussenblatt and S. M. Whitcup, Eds., pp. 76–113, Mosby-Elesvier, 4th edition, 2010. View at Google Scholar
  2. P. P. Sfikakis, P. G. Theodossiadis, C. G. Katsiari, P. Kaklamanis, and N. N. Markomichelakis, “Effect of infliximab on sight-threatening panuveitis in Behçet's disease,” The Lancet, vol. 358, no. 9278, pp. 295–296, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. I. Tugal-Tutkun, A. Mudun, M. Urgancioglu et al., “Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial,” Arthritis and Rheumatism, vol. 52, no. 8, pp. 2478–2484, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Díaz-Llopis, D. Salom, C. Garcia-De-Vicuña et al., “Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients,” Ophthalmology, vol. 119, no. 8, pp. 1575–1581, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Arayssi, R. Hamra, F. Homeidan et al., “The efficacy of a single dose of infliximab in the treatment of Behçet's disease uveitis,” Clinical and Experimental Rheumatology, vol. 23, no. 3, p. 427, 2005. View at Google Scholar · View at Scopus
  6. M. Cordero-Coma, T. Yilmaz, and S. Onal, “Systematic review of anti-tumor necrosis factor-alpha therapy for treatment of immune-mediated uveitis,” Ocular Immunology and Inflammation, vol. 21, no. 1, pp. 19–27, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Sakai, H. Watanabe, K. Kuroyanagi et al., “Health- and vision-related quality of life in patients receiving infliximab therapy for Behçet uveitis,” British Journal of Ophthalmology, vol. 97, no. 3, pp. 338–342, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Levy-Clarke, D. A. Jabs, R. W. Read, J. T. Rosenbaum, A. Vitale, and R. N. Van Gelder, “Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders,” Ophthalmology, vol. 121, no. 3, pp. 785–796, 2014. View at Publisher · View at Google Scholar
  9. Z. Ash and P. Emery, “Golimumab -a new tool in the armoury against inflammatory arthritis,” Annals of Medicine, vol. 43, no. 2, pp. 133–141, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Cordero-Coma, D. Salom, M. Díaz-Llopis, M. J. López-Prats, and S. Calleja, “Golimumab for uveitis,” Ophthalmology, vol. 118, no. 9, pp. 1892–e4, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. M. William, S. Faez, G. N. Papaliodis, and A.-M. Lobo, “Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis,” Journal of Ophthalmic Inflammation and Infection, vol. 2, no. 4, pp. 231–233, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Faez, A. M. Lobo, L. Sobrin, and G. N. Papaliodis, “Treatment of seronegative spondyloarthropathy-associated uveitis with golimumab: retrospective case series,” Clinical & Experimental Ophthalmology, 2013. View at Publisher · View at Google Scholar
  13. R. B. Nussenblatt, A. G. Palestine, C.-C. Chan, and F. Roberge, “Standardization of vitreal inflammatory activity in intermediate and posterior uveitis,” Ophthalmology, vol. 92, no. 4, pp. 467–471, 1985. View at Google Scholar · View at Scopus
  14. D. A. Jabs, “Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop,” American Journal of Ophthalmology, vol. 140, no. 3, pp. 509–516, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Santos Lacomba, C. Marcos Martín, J. M. Gallardo Galera et al., “Aqueous humor and serum tumor necrosis factor-α in clinical uveitis,” Ophthalmic Research, vol. 33, no. 5, pp. 251–255, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Sakaguchi, S. Sugita, K. Sagawa, K. Itoh, and M. Mochizuki, “Cytokine production by T cells infiltrating in the eye of uveitis patients,” Japanese Journal of Ophthalmology, vol. 42, no. 4, pp. 262–268, 1998. View at Publisher · View at Google Scholar · View at Scopus
  17. A. D. Dick, J. V. Forrester, J. Liversidge, and A. P. Cope, “The role of tumour necrosis factor (TNF-α) in experimental autoimmune uveoretinitis (EAU),” Progress in Retinal and Eye Research, vol. 23, no. 6, pp. 617–637, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. L. I. Kump, R. A. C. Castañeda, S. N. Androudi, G. F. Reed, and C. S. Foster, “Visual outcomes in children with juvenile idiopathic arthritis-associated uveitis,” Ophthalmology, vol. 113, no. 10, pp. 1874–1877, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. W. J. Power, A. Rodriguez, M. Pedroza-Seres, and C. S. Foster, “Outcomes in anterior uveitis associated with the HLA-B27 haplotype,” Ophthalmology, vol. 105, no. 9, pp. 1646–1651, 1998. View at Publisher · View at Google Scholar · View at Scopus
  20. O. M. Durrani, N. N. Tehrani, J. E. Marr, P. Moradi, P. Stavrou, and P. I. Murray, “Degree, duration, and causes of visual loss in uveitis,” British Journal of Ophthalmology, vol. 88, no. 9, pp. 1159–1162, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. C. W. T. A. Lardenoye, B. van Kooij, and A. Rothova, “Impact of macular edema on visual acuity in uveitis,” Ophthalmology, vol. 113, no. 8, pp. 1446–1449, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. E. Giraudo, L. Primo, E. Audero et al., “Tumor necrosis factor-α regulates expression of vascular endothelial growth factor receptor-2 and of its co-receptor neuropilin-1 in human vascular endothelial cells,” Journal of Biological Chemistry, vol. 273, no. 34, pp. 22128–22135, 1998. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Hangai, S. He, S. Hoffmann, J. I. Lim, S. J. Ryan, and D. R. Hinton, “Sequential induction of angiogenic growth factors by TNF-α in choroidal endothelial cells,” Journal of Neuroimmunology, vol. 171, no. 1-2, pp. 45–56, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Rothova, “Inflammatory cystoid macular edema,” Current Opinion in Ophthalmology, vol. 18, no. 6, pp. 487–492, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Calleja, M. Cordero-Coma, E. Rodriguez, M. Llorente, M. Franco, and J. G. Ruiz de Morales, “Adalimumab specifically induces CD3+ CD4+ CD25high Foxp3+ CD127 T-regulatory cells and decreases vascular endothelial growth factor plasma levels in refractory immuno-mediated uveitis: a non-randomized pilot intervention study,” Eye, vol. 26, no. 3, pp. 468–477, 2012. View at Publisher · View at Google Scholar · View at Scopus